Victoria Times Colonist Because my blood pressure was difficult to control following surgery, I was prescribed amlodipine and metoprolol. Approximately 10 years ago, I was diagnosed with a 65 per cent to 70 per cent blocked right carotid artery. The vascular surgeon who ... and more »
Toronto NewsFIX ... on average, while the other aimed at a more conventional target of 141/85 mm Hg. All participants took one of three classes of drugs: metoprolol, a beta-blocker, ramipril, an angiotensin-converting enzyme (ACE) inhibitor, or amlodipine , which is a ...
U.S. News & World Report (blog) Over two thirds (71 percent) of Medicare beneficiaries age 65 and older purchased cardiovascular medicines in 2010, which include Lisinopril, Metoprolol, Amlodipine , Hydrochlorothiazide and Furosemide. [Read: How to Budget for Health Costs in ...
Toronto NewsFIX During this time, they were treated with ramipril, amlodipine or metoprolol – either singly or in combination. The participants were divided into two groups, according to the blood pressure reduction goal. One group was to achieve a measurement of 140 ... and more »
Valley News Amlodipine besylate, another blood pressure medication, is known to effectively treat the problem and is tolerated well by most patients, Entwisle said. The drug most commonly prescribed to Medicare patients, in New Hampshire and nationally, is ...
TheHeart.Org Products in Japan that contain valsartan include Diovan, Co-Diovan (valsartan and hydrochlorothiazide), and Exforge (valsartan and amlodipine ). To heartwire, Novartis said it has undertaken its own review of the Japanese adverse-event-report data ... and more »
The Pharma Letter Doing rather better was Lyrica ( pregabalin ), for epilepsy, fibromyalgia and neuropathic pain, which increased 10% to $1.13 billion, while the kidney cancer treatment Sutent (sunitinib) slipped 2% to $312 million. The COX-2 inhibitor Celebrex (celecoxib ... and more »
PharmaTimes Lyrica ( pregabalin ), for epilepsy, fibromyalgia and neuropathic pain, increased 10% to $1.13 billion, while the kidney cancer treatment Sutent (sunitinib) slipped 2% to $312 million. The COX-2 inhibitor Celebrex (celecoxib) rose 8% to $715 million. As ... and more »
